IZERVAY (avacincaptad pegol sodium/pf)

There are 1 contraindications. Absolute contraindication.

Contraindication List
Ocular infection

There are 1 severe contraindications. Adequate patient monitoring is recommended for safer drug use.

Severe List
Ocular inflammation

There are 0 moderate contraindications.

There are 4 severe adverse reactions.

More Frequent	Less Frequent
Neovascular age-related macular degeneration Ocular hypertension	None.

Rare/Very Rare
Endophthalmitis Retinal detachment

There are 5 less severe adverse reactions.

More Frequent	Less Frequent
Blurred vision Conjunctival hemorrhage	Blepharitis Ocular pain Vitreous floater

Rare/Very Rare
None.

There are no adequate data regarding the use of avacincaptad pegol in pregnant women. Use of avacincaptad pegol in pregnancy may be considered following an assessment of the risks and benefits. No maternal or embryofetal adverse effects were observed in animal studies; however, in rat studies, an increase in the incidence of non-adverse skeletal variation, described as short thoracolumbar supernumerary ribs was observed.

It is not known whether avacincaptad pegol is distributed into human milk, or if the drug has any effects on the breastfed infant or on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for avacincaptad pegol, and any potential adverse effects on the breastfed infant from the drug or underlying maternal condition.

Among the patients who received avacincaptad pegol in clinical studies, 90% were >=65 years of age and 61% were >=75 years of age. No differences in efficacy or safety of avacincaptad pegol were observed with increasing age, and no dosage adjustments are recommended based on age.